Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
梯瓦制药的授权版优降糖胰岛素在美国上市
- Generic Victoza is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market.
-
This launch adds to Teva's continued commitment to its complex generic medicine portfolio.
- Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
- 普通维多利亚是首个通用的GLP-1，支持美国市场在这一类疗法的需求增加。
-
此次发布是Teva继续致力于其复杂通用药品组合的一部分。
- 利拉鲁肽注射液适用于改善10岁及以上的成人和儿童2型糖尿病患者的血糖控制，并且降低已建立心血管疾病的成人2型糖尿病患者的心血管事件风险。